Amber Therapeutics closes $100 million Series A financing led by New Enterprise Associates to advance Amber-UI neuromodulation therapy for mixed urinary incontinence

Jun 10, 2024•over 1 year ago

Amount Raised

$100 Million

Round Type

series a

LondonTherapeuticsBiotechnologyHealth Care

Investors

8 VcOxford Science EnterprisesIntuitive VenturesLightstone VenturesF Prime CapitalNew Enterprise Associates

Description

Amber Therapeutics, a UK-based medical technology company, has successfully closed its Series A financing round, raising a total of $100 million from leading healthcare and technology investors in the US and UK. The funding will be used to advance Amber-UI, a breakthrough adaptive neuromodulation therapy, towards US FDA approval to treat mixed urinary incontinence (MUI).

Company Information

Company

Amber Therapeutics

Location

London, England, United Kingdom

About

Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally transform outcomes in areas of unmet clinical need. We have since grown into a multidisciplinary team, combining deep medical device experience with a culture and mindset focused on transformational innovation. Amber UI is the company’s first therapy, aiming to restore normal physiological function in women suffering with mixed urinary incontinence.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends